PDGFRB and acute myeloid leukemia: ABL1, ABL2, PDGFRB, JAK2, FGFR1, and NTRK3 fusions have been reported responsive to targeted kinase inhibitors [20–22], and they were detected in 9.4% of our cases (21.9% in B-ALL, 20.8% in MPAL, 2.8% in T-ALL, and 1.3% in AML) (Fig. 3).